Floatz logo

Darovasertib

Ocular Melanoma

St Vincent's Hospital, SydneySmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Ocular Melanoma cohort.

Asset / SponsorPhaseRating
Belzupacap Sarotalocan
Aura Biosciences
Phase 2BB
Ipilimumab
University of Michigan Rogel Cancer Center
Phase 2BB
Poly-Iclc
Craig L Slingluff, Jr
Phase 2B
Nivolumab
University of Michigan Rogel Cancer Center
Phase 2B
Aflibercept
Centre Hospitalier Universitaire de Nice
Phase 3B

View all 25 →

Same molecule, other indications

Darovasertib is also rated in:

uveal melanomaActive
BB
Indicative · Phase 3
69 / 100
View asset →
cutaneous melanomaActive
CC
Indicative · Phase 1/2
45 / 100
View asset →
colorectal cancerActive
CC
Indicative · Phase 1/2
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →